小肠菌群分布及粘膜结构对胆道闭锁小儿肝移植的影响

注册号:

Registration number:

ChiCTR1900023843 

最近更新日期:

Date of Last Refreshed on:

2019-06-14 10:48:07 

注册时间:

Date of Registration:

2019-06-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

小肠菌群分布及粘膜结构对胆道闭锁小儿肝移植的影响

Public title:

Effects of intestinal flora distribution and mucosal structure on pediatric liver transplantation with biliary atresia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

小肠菌群分布及粘膜结构对胆道闭锁小儿肝移植的影响

Scientific title:

Effects of intestinal flora distribution and mucosal structure on pediatric liver transplantation with biliary atresia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙超 

研究负责人:

孙超 

Applicant:

Chao Sun 

Study leader:

Chao Sun 

申请注册联系人电话:

Applicant telephone:

+86 13920185470

研究负责人电话:

Study leader's
telephone:

+86 13920185470

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sunchaodoc@163.com

研究负责人电子邮件:

Study leader's E-mail:

sunchaodoc@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市南开区复康路24号

研究负责人通讯地址:

天津市南开区复康路24号

Applicant address:

24 Fukang Road, Nankai District, Tianjin, China

Study leader's address:

24 Fukang Road, Nankai District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

300192

研究负责人邮政编码:

Study leader's postcode:

300192

申请人所在单位:

天津市第一中心医院

Applicant's institution:

Tianjin First Center Hospital

研究负责人所在单位:

天津市第一中心医院

Affiliation of the Leader:

Tianjin First Center Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018N094KY

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津市第一中心医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin First Center Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2018-09-11 00:00:00

伦理委员会联系人:

刘玥

Contact Name of the ethic committee:

Liu Yue

伦理委员会联系地址:

天津市南开区复康路24号

Contact Address of the ethic committee:

24 Fukang Road, Nankai District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 022-23626542

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津市第一中心医院

Primary sponsor:

Tianjin First Center Hospital

研究实施负责(组长)单位地址:

天津市南开区复康路24号

Primary sponsor's address:

24 Fukang Road, Nankai District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

南开区

Country:

China

Province:

Tianjin

City:

Nankai District

单位(医院):

天津市第一中心医院

具体地址:

复康路24号

Institution
hospital:

Tianjin First Center Hospital

Address:

24 Fukang Road

经费或物资来源:

天津市科委天津市器官移植临床研究中心项目

Source(s) of funding:

Tianjin Clinical Research Center for Organ Transplantation

研究疾病:

胆道闭锁  

Target disease:

Biliary Atresia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

明确肠道菌群分布对患儿胆管炎的影响,不同部位肠道菌群种类及丰度对胆道闭锁小儿肝硬化程度的影响,明确移植时肠道菌群分布情况及空肠粘膜结构变化对肝移植术后感染及排斥反应的影响。  

Objectives of Study:

To clarify the influence of intestinal flora distribution on cholangitis in children with biliary atresia, the influence of different types of intestinal flora and abundance on the degree of cirrhosis of biliary atresia patients, and the distribution of intestinal flora and jejunal mucosal structure changes on infection and rejection after transplantation.

药物成份或治疗方案详述:

研究肝移植手术的胆道闭锁小儿,使用16s焦磷酸测序方法研究肝移植时小儿空场上段菌群分布、肠粘膜结构及移植前粪便菌群分布情况。同时肝移植术中留取血清查内毒素,留取腹水培养,明确菌群异位情况。观察肝移植术后早期(术后3个月内)排斥反应(病理证实)发生情况,感染发生情况。明确移植时肠道菌群分布情况对肝移植术后感染及排斥反应的影响。 

Description for medicine or protocol of treatment in detail:

The biliary atresia patients who received liver transplantation were studied. The 16s pyrosequencing method was used to study the distribution of intestine. The structure of intestinal mucosa and the distribution of fecal flora before transplantation. At the same time, the liver was collected for serum endotoxin, and the ascites culture was taken to confirm the ectopic condition of the flora. The incidence of infection (pathological confirmation) and the occurrence of infection were observed post liver transplantation (within 3 months after surgery).  

纳入标准:

Inclusion criteria

排除标准:

血型不合肝脏移植,再次肝脏移植。

Exclusion criteria:

ABO incompatible liver transplantation; and liver retransplantation.

研究实施时间:

Study execute time:

From 2019-07-01 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-07-01 00:00:00 To 2020-06-30 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

20

Group:

1

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

组别:

2

样本量:

10

Group:

2

Sample size:

干预措施:

口服益生菌

干预措施代码:

Intervention:

probiotics

Intervention code:

组别:

3

样本量:

10

Group:

3

Sample size:

干预措施:

利福昔明

干预措施代码:

Intervention:

Rifaximin

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市第一中心医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin First Center Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

排斥

指标类型:

主要指标

Outcome:

rejection

Type:

Primary indicator

测量时间点:

测量方法:

检测肝功能、肝穿刺活检

Measure time point of outcome:

Measure method:

hepatic function test, liver biopsy

指标中文名:

16s rDNA的序列变异和丰度

指标类型:

主要指标

Outcome:

Sequence Variation and Abundance of 16S rDNA

Type:

Primary indicator

测量时间点:

肝移植术前及术后1周,1个月,3个月

测量方法:

Measure time point of outcome:

at preoperation, 1 week, 1 month and 3 months postoperation

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

小肠粘膜

组织:

小肠

Sample Name:

mucosa of intestine

Tissue:

intestine

人体标本去向

使用后销毁  

说明

检测后销毁

Fate of sample:

Destruction after use  

Note:

Destuction after use

标本中文名:

血液

组织:

外周血

Sample Name:

Blood

Tissue:

Blood

人体标本去向

使用后销毁  

说明

用后销毁

Fate of sample:

Destruction after use  

Note:

Destruction after use

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心 ChiCTR非原始数据共享平台,请修改,ResMan为临床试验数据管理共享平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese clinical trial registry ChiCTR非原始数据共享平台,请修改,ResMan为临床试验数据管理共享平台

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-06-14 10:48:07